UBRELVY (ubrogepant) is a medication that has patent protections [1]. Patent expirations for pharmaceuticals like UBRELVY can lead to the introduction of generic versions, which typically lowers drug costs [1].
When does UBRELVY's patent protection end?
Specific patent expiration dates for UBRELVY are not publicly detailed here, but patents for prescription drugs generally last for 20 years from the filing date [1]. This period can be extended through patent term adjustments granted by regulatory bodies [1].
What happens when UBRELVY's patents expire?
Once the patents expire and any other market exclusivities cease, other companies can manufacture and sell generic versions of UBRELVY [1]. This increased competition can significantly reduce the price of the medication [1].
How do drug patents affect access to medications like UBRELVY?
Drug patents grant exclusive rights to the developing company, preventing others from making or selling the drug for a set period [1]. This exclusivity is intended to allow companies to recoup their research and development costs. After expiration, generic competition can improve affordability and patient access [1].
Are there alternatives to UBRELVY?
UBRELVY is used to treat migraine headaches. Other acute treatments for migraine include triptans and other CGRP receptor antagonists [2]. The choice of treatment depends on individual patient needs and responses [2].
Who makes UBRELVY?
UBRELVY is manufactured by AbbVie [3].